BLYS Trademark

Trademark Overview


On Friday, September 3, 1999, a trademark application was filed for BLYS with the United States Patent and Trademark Office. The USPTO has given the BLYS trademark a serial number of 75792415. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, March 11, 2011. This trademark is owned by Human Genome Sciences, Inc.. The BLYS trademark is filed in the Pharmaceutical Products category with the following description:

proteins for the treatment of immune deficiency syndromes, cancer, AIDS, infectious diseases, allergies, asthma and autoimmunity; nucleic acids for the treatment of immune deficiency syndromes, cancer, AIDS, infectious diseases, allergies, asthma and autoimmunity; pharmaceutical preparations containing proteins for the treatment of immune deficiency syndromes, cancer, AIDS, infectious diseases, allergies, asthma and autoimmunity; pharmaceutical preparations containing nucleic acids for the treatment of immune deficiency syndromes, cancer, AIDS, infectious diseases, allergies, asthma and autoimmunity; proteins for the enhancement of B cell activity and immunoglobulin production following organ transplant, bone marrow transplant, vaccine administration, immunosuppression, chemotherapy, radio therapy, antibiotic therapy, and gene therapy; nucleic acids for the enhancement of B cell activity and immunoglobulin production following organ transplant, bone marrow transplant, vaccine administr...

General Information


Serial Number75792415
Word MarkBLYS
Filing DateFriday, September 3, 1999
Status710 - CANCELLED - SECTION 8
Status DateFriday, March 11, 2011
Registration Number2871946
Registration DateTuesday, August 10, 2004
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, January 30, 2001

Trademark Statements


Goods and Servicesproteins for the treatment of immune deficiency syndromes, cancer, AIDS, infectious diseases, allergies, asthma and autoimmunity; nucleic acids for the treatment of immune deficiency syndromes, cancer, AIDS, infectious diseases, allergies, asthma and autoimmunity; pharmaceutical preparations containing proteins for the treatment of immune deficiency syndromes, cancer, AIDS, infectious diseases, allergies, asthma and autoimmunity; pharmaceutical preparations containing nucleic acids for the treatment of immune deficiency syndromes, cancer, AIDS, infectious diseases, allergies, asthma and autoimmunity; proteins for the enhancement of B cell activity and immunoglobulin production following organ transplant, bone marrow transplant, vaccine administration, immunosuppression, chemotherapy, radio therapy, antibiotic therapy, and gene therapy; nucleic acids for the enhancement of B cell activity and immunoglobulin production following organ transplant, bone marrow transplant, vaccine administration, immunosuppression, chemotherapy, radio therapy, antibiotic therapy, and gene therapy; pharmaceutical preparations containing proteins for the enhancement of B cell activity and immunoglobulin production following organ transplant, bone marrow transplant, vaccine administration, immunosuppression, chemotherapy, radio therapy, antibiotic therapy, and gene therapy; and pharmaceutical preparations containing nucleic acids for the enhancement of B cell activity and immunoglobulin production following organ transplant, bone marrow transplant, vaccine administration, immunosuppression, chemotherapy, radio therapy, antibiotic therapy, and gene therapy
Pseudo MarkBLYS

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, March 11, 2011
Primary Code005
First Use Anywhere DateSunday, November 30, 2003
First Use In Commerce DateSunday, November 30, 2003

Trademark Owner History


Party NameHuman Genome Sciences, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressRockville, MD 20850

Party NameHuman Genome Sciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRockville, MD 20850

Party NameHuman Genome Sciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRockville, MD 20850

Trademark Events


Event DateEvent Description
Friday, March 11, 2011CANCELLED SEC. 8 (6-YR)
Tuesday, November 28, 2006APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, November 28, 2006TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, August 10, 2004REGISTERED-PRINCIPAL REGISTER
Monday, May 24, 2004ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, May 12, 2004STATEMENT OF USE PROCESSING COMPLETE
Saturday, April 24, 2004USE AMENDMENT FILED
Tuesday, May 4, 2004CASE FILE IN TICRS
Monday, April 26, 2004TEAS STATEMENT OF USE RECEIVED
Monday, April 26, 2004ASSIGNED TO EXAMINER
Monday, September 15, 2003EXTENSION 5 GRANTED
Tuesday, September 9, 2003EXTENSION 5 FILED
Tuesday, September 9, 2003TEAS EXTENSION RECEIVED
Saturday, June 7, 2003EXTENSION 4 GRANTED
Thursday, April 24, 2003EXTENSION 4 FILED
Thursday, April 24, 2003PAPER RECEIVED
Friday, December 6, 2002EXTENSION 3 GRANTED
Thursday, October 24, 2002EXTENSION 3 FILED
Thursday, October 24, 2002PAPER RECEIVED
Thursday, May 2, 2002EXTENSION 2 GRANTED
Tuesday, April 23, 2002EXTENSION 2 FILED
Monday, April 15, 2002EXTENSION 1 GRANTED
Friday, October 19, 2001EXTENSION 1 FILED
Tuesday, April 24, 2001NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 30, 2001PUBLISHED FOR OPPOSITION
Friday, December 29, 2000NOTICE OF PUBLICATION
Wednesday, September 6, 2000APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 21, 2000CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, December 22, 1999NON-FINAL ACTION MAILED
Friday, December 17, 1999ASSIGNED TO EXAMINER